Skip to main content
. 2020 Jan 8;9(1):174. doi: 10.3390/jcm9010174

Table 1.

Description of the study cohorts.

Septic Shock (n = 20) Cardiac Surgery (CABG, n = 20) Major Abdominal Surgery (MAS, n = 20) Control Patients (CTRL, n = 20)
General Characteristics
Age (years) 69 (64.3–74) 70 (62–79) 68 (54–70) 69 (66.3–74.3)
Sex (% male) 70 75 60 70
BMI (kg·m−2) 27.9 (21.7–32.6) 30 (27.6–36.5) 24 (22.4–26.9) 27 (23.2–29.2)
ASA
I
II
III
IV
V

0
0
10 (50%)
9 (45%)
1 (5%)

0
0
18 (90%)
2 (10%)
0

1 (5%)
8 (40%)
11 (55%)
0
0

1 (5%)
6 (30%)
13 (65%)
0
0
SOFA onset 10.5 (10–12.5) NA NA NA
SOFA 24 h 11.5 (8–13) 3 (1–3.8) 2 (0–3) NA
SOFA 72 h 9 (5.5–14.5) 3.5 (1–4.8) 3.5 (1.8–4.8) NA
Focus of infection
Abdominal
Pulmonary
Urological
Soft tissue

12 (60%)
3 (15%)
3 (15%)
2 (10%)
NA NA NA
Type of abdominal surgery
Whipple Procedure
Open Partial colectomy
Esophagus resection
Other major abdominal surgery
NA NA
8 (40%)
4 (20%)
4 (20%)
4 (20%)
NA
Duration of Cardiopulmonary bypass NA 93 (74.8–111) NA NA
In-hospital death (%) 35 0 5 0
Preexisting Diseases
Diabetes mellitus 9 (45%) 12 (60%) 1 (5%) 8 (40%)
Chronic kidney failure 4 (20%) 5 (25%) 1 (5%) 3 (15%)
Arteriosclerosis 14 (70%) 20 (100%) 5 (25%) 14 (70%)
Malignant cancerous disease 7 (35%) 0 13 (65%) 7 (35%)
Anticoagulatory Therapy
Prophylactic heparinization onset/preoperative 10 (50%) 20 (100%) 20 (100%) 15 (75%)
Prophylactic heparinization postoperative 0 0
Prophylactic heparinization 24 h 12 (60%) 18 (90%) 18 (90%)
Prophylactic heparinization 72 h 11 (55%) 16 (80%) 18 (90%)
Therapeutic heparinization onset/preoperative 8 (40%) 0 0 5
Therapeutic heparinization postoperative 0 1 (5%)
Therapeutic heparinization 24 h 6 (30%) 2 (10%) 1 (5%)
Therapeutic heparinization 72 h 7 (35%) 3 (15%) 1 (5%)

Data are shown as median (interquartile range) or as an absolute number and percentage (n (%)) of the study group. Abbreviations: ASA: American Society of Anesthesiology Score; BMI: Body Mass Index; SOFA: Sepsis-related Organ Failure Assessment; NA: not applicable.